We firstly reported that ANRIL could promote the tumor cell proliferation, invasion, migration, and exacerbates chemotherapy resistance to gemcitabine of pancreatic cancer by managing miR-181a/ HMGB1 axis and restraining cell autophagy, which reveal the role of ANRIL and miR-181a in therapy of pancreatic. This evidence concerns the gene CDKN2B-AS1 and neoplasm.